Gross margin is the number that turns a launch into a business
Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.
Growth is everywhere. Margin is not.
Read the third-quarter releases in sequence and the headline numbers blur together. Tonix reported TONMYA net sales of about $15 million, up 37% from the second quarter. Kura's KOMZIFTI grew 53% sequentially to $13.9 million. ADC Therapeutics booked $21 million in net product revenue. Autolus reported $41.2 million for AUCATZYL, up 95% year over year. Each is a launch moving in the right direction.
Growth of that kind now tells an executive very little, because nearly every commercial-stage company can produce it. The sharper question is what each incremental dollar of revenue costs to deliver. On that question the quarter separates companies more cleanly than any growth rate does.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Reimbursement, not approval, is the commercial gate, and leaders should plan accordingly
This month's payer decisions from CMS, China's NRDL and Medicare show that price and access are set by policy calendars. Companies that treat them as afterthoughts will pay for it.
Show your working: launch revenue is the lagging indicator, and this season proves it
Headline growth rates from small launches are easy to produce and hard to compare. The results that persuade pair revenue with evidence of demand and a plan the economics can fund.
The first launch is a down payment: this earnings season rewards the label that funds the next one
Kura, Autolus, ADC Therapeutics and others are using first-product revenue to underwrite a second act. The risk is trying to do both at once.